Previous 10 | Next 10 |
WATERTOWN, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:3...
2023-07-18 17:26:50 ET Gainers: Ribbon Communications ( NASDAQ: RBBN ) +7% . Terns Pharmaceuticals ( TERN ) +3% . Arrival ( ARVL ) +3% . EyePoint Pharmaceuticals ( EYPT ) +3% . Lyra Therapeutics ( LYRA ) +3% . ...
2023-07-10 07:46:31 ET EyePoint ( NASDAQ: EYPT ) has appointed Jay S. Duker, M.D. as Chief Executive Officer (CEO). Duker has transitioned from his most recent role as Chief Operating Officer (COO) and President and has also been appointed to the board of the com...
– Jay S. Duker, M.D., Previously President and Chief Operating Officer, Appointed President and Chief Executive Officer – – Nancy S. Lurker Transitions to Executive Vice Chair of the Board of Directors Pursuant to Long Term Succession Plan – WAT...
2023-06-13 17:41:09 ET Gainers: Inventiva ( IVA ) +42% . NOVONIX ( NVX ) +5% . EyePoint Pharmaceuticals ( EYPT ) +5% . 908 Devices ( MASS ) +5% . Vera Therapeutics ( VERA ) +5% . Losers: Microvision ( MVIS ...
– Significant investigator and patient interest drove strong recruitment of 77 patients exceeding the 60 patient target – – Topline PAVIA data anticipated in 2Q 2024 – WATERTOWN, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, I...
WATERTOWN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that George Elston, Chief Financial Officer of EyePoint...
2023-05-30 08:00:48 ET Summary EyePoint is a $200m market cap biotech focused on eye disease. The company's long-acting Durasert technology has been supporting its commercial product, YUTIQ, which earned $28m of revenues in FY22. EyePoint recently announced however that it had...
2023-05-18 10:52:19 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alimera Sciences (NASDAQ: ALIM ) stock is taking off on Thursday after signing a major deal with EyePoint Pharmaceuticals (NASDAQ: EYPT ). That agreement...
–$75M paid at closing with an additional $7.5M payable in equal quarterly installments in 2024 – All outstanding bank debt retired and expected cash runway extended into 2025 – EyePoint well-capitalized beyond key EYP-1901 Phase 2 DAVIO 2 and PAVIA clinical ...
News, Short Squeeze, Breakout and More Instantly...
EyePoint Pharmaceuticals Inc. Company Name:
EYPT Stock Symbol:
NASDAQ Market:
EyePoint Pharmaceuticals Inc. Website:
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 – – Positive twelve-month safety and efficacy data from Phase 2 DAVIO 2 clinical tria...
WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company will host an R...